News & Updation
Best Paper Awards
World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.
Best Article of current issue
Download Article : Click here
HORMONE RECEPTOR AND HER-2 NEU STATUS IN BREAST CANCER PATIENTS ATTENDING RADIOTHERAPY OPD: AN INSTITUTIONAL EXPERIENCE
Dr. Swapan Kumar Mallick*, Dr. Arup Chakraborty, Dr. Arista Lahiri, Dr. Md Asifullah, Dr. Rajiv Lochan Jena and Dr. Madhumay Pal
Introduction: In breast cancer, hormonal status plays a very pivotal role in its etiology, prognosis and treatment in adjuvant as well as metastatic setting. This study explored hormonal profiles of the patients and metastasis in breast cancer. Materials & Methods: Breast cancer patient data were analysed retrospectively from institutional records during the study period from 1st January 2013 to 31st December 2017. The collected data was compiled into EpiInfo 7 software and subsequently analysis of data was done using SPSS software, version 16 and results are mentioned with the help of tables. Result and Discussion: Most of the breast cancer patients were of the age 40-60 years. Most of the patients had locally advanced carcinoma, 49.2%. Hormonal status was known for 82.2% of the patients. In our study ER positive, PR positive & Her-2 positive were 38.4%, 41.09% & 36.9% respectively of the whole sample and 46.67%, 50% & 45% respectively among the hormonal status known patients. Those who received hormonal therapy, were 31.5% amongst all the available records. Patients with HER2, ER & PR status positive (21.67%) and HER2 negative, but positive for ER & PR (16.67%) received hormonal therapy. While 23.33% patients did not receive hormonal therapy, being negative for HER2, ER & PR; it was also observed that 21.67% patients were not given any hormonal therapy, being ER & PR negative but HER2 positive. Conclusion: ER/PR positive was the most frequently observed hormonal profile in our population and this population is eligible for hormonal therapy.[Full Text Article]